There are about 36818 clinical studies being (or have been) conducted in China. The country of the clinical trial is determined by the location of where the clinical research is being studied. Most studies are often held in multiple locations & countries.
This is a single-center, open-label randomized controlled Phase II clinical study to observe and evaluate the efficacy and safety of Sovantinib in combination with AG versus AG first-line treatment in patients with locally advanced or metastatic pancreatic cancer. According to the literature analysis, the mPFS of gemcitabine combined with albumin-binding paclitaxel in first-line treatment of metastatic pancreatic cancer was 3.56 months in historical controlled studies, and the expected PFS of soantinib combined with AG regimen increased from 2.06 months to 4.5 months after 2 cycles of AG regimen. Follow-up time was 12 months and enrollment time was 18 months. α=0.05 and β=0.2 were used for bilateral test, and the PASS 22 software was used for analysis. The sample size of AG group in the control group was 29 cases, and that of AG combined with Solvatinib in the experimental group was 29 cases. The total sample size needed to be enrolled was 58 cases, and a total of 65 subjects were required according to the 10% shedding rate. This study was divided into three stages: screening period, treatment period and follow-up period. During treatment, tumor status was assessed by imaging every 6 weeks (±7 days) until disease progression (PD, RECIST 1.1) or death (during patient treatment) or toxicity intolerance or other protocol criteria for discontinuation of study therapy were met. A maximum of 6 treatment cycles of AG chemotherapy were specified, and soantinib was continued until disease progression (PD, RECIST 1.1) or death (during patient treatment) or toxicity intolerance or other criteria for discontinuation of study therapy were met in the protocol. Tumor treatment and survival status after disease progression were recorded. Safety outcomes included AE, changes in laboratory test values, vital signs and electrocardiogram changes.
This study aims to assess the clinical efficacy and safety of obinutuzumab in Chinese patients with indolent non-Hodgkin B-cell Lymphoma (predominantly Follicular lymphoma and Marginal zone lymphoma) in a real-world setting.
This study aims to design and train a deep learning model for the diagnosis of different arrhythmias.
To evaluate the safety and tolerability of SSGJ-613 after multiple subcutaneous injections in healthy subjects.
The goal of this Phase 2 trial is to evaluate a neoadjuvant treatment mode for locally advanced rectal cancer (LARC), consisting of radiotherapy and concurrent Trifluridine/Tipiracil (TAS-102). The main questions it aims to answer are: (i) whether TAS-102 is effective in treating LARC, when combined with radiotherapy; (ii) whether TAS-102 is safe in combination with radiotherapy. Participants will receive one cycle of TAS-102 chemotherapy and neoadjuvant radiotherapy based on intensity-modulated technique. Then the ones with a possibility of R0 resection will receive radical surgery followed by 6 cycles of adjuvant XELOX (capecitabine plus oxaliplatin) chemotherapy.
The goal of this prospective, exploratory, non-intervention, multi-center, real-world study is to investigate the predictive value of HBV pgRNA in the occurrence of long-term outcomes under antiviral therapy in patients with chronic hepatitis B. Participants will take the necessary clinical examination and blood draw during the patient's treatment and follow-up, and all the treatment is determined by clinicians.
The investigation of biomarkers for immune status and metabolic state, as well as host microbiota composition, in patients with ventricular arrhythmias before and after radiofrequency ablation, can provide new insights for specific and personalized treatment. This can help establish early prediction and prognosis models and provide a basis for clinically effective diagnosis and treatment.
In this study, by establishing a clinical cohort of infective endocarditis, we observed the natural prognosis and influencing factors in the process of disease development and regression; we used multi-omics technology to understand the prognostic value of its biomarkers, and provided new ideas and evidence for the pathogenesis, clinical diagnosis and treatment of IE.
A multicenter, retrospective study to evaluate the real-world efficacy of the Fabulous thoracic aortic stent system in the treatment of Stanford Type B aortic dissection.
This study intends to analyze the characteristics between peripapillary retinal nerve fiber layer thickness and peripapillary area in high myopia with or without glaucoma